Lead Product(s) : Iohexol
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
Details : Iohexol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fabry Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2013
Lead Product(s) : Iohexol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Taejoon Pharm. Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Chest CT Using Low-concentration Iodine Contrast Media
Details : Iohexol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lung Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Iohexol
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Taejoon Pharm. Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iohexol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Bayer AG | GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
Details : Iohexol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypothyroidism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2018
Lead Product(s) : Iohexol
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Bayer AG | GUERBET
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight
Details : Iohexol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2018
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
Details : Omnipaque is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 21, 2015
Lead Product(s) : Iohexol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
